Shots:
- The EC has approved Welireg for VHL-related localized RCC, CNS hemangioblastomas, or pNET unsuitable for localized procedures and advanced ccRCC post-PD-1/PD-L1 inhibitors or VEGF therapies progression across EU member states, as well as Iceland, Liechtenstein & Norway
- Approval for VHL-related tumors was based on P-II (LITESPARK-004) study (n=61), showing ORR of 49% (all PRs), with 56% maintaining response (RCC); 63% (CR: 4%, PR: 58%), with 73% maintaining response (CNS hemangioblastomas) & 83% (CR: 17%, PR: 67%), with 50% maintaining response for ≥12mos. (pNET); mDoR not reached
- Approval for ccRCC was based on P-III (LITESPARK-005) study (n=746), depicting reduced disease progression or death risk by 25% vs everolimus, with mPFS of 5.6mos., ORR of 22% (CR: 3%, PR: 19%) vs 4% (PR: 4%)
Ref: Merck | Image: Merck
Related News:- Merck Initiates P-III (waveLINE-010) Trial of Zilovertamab Vedotin to Treat Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
